Trending...
- Knobull Helps Followers Make The Most Of Small Living Space
- Eric Bohannon Joins Buoy Health Board of Directors
- Procurement Partners Welcomes Troy Thibodeau as Chief Marketing Officer
BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals, Inc. (1228.HK), a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced that it has appointed Pauline Li, MD, to the position of Senior Vice President of Clinical Development and Operations, effective as of May 8.
Dr. Li brings to CANbridge a wealth of international clinical development experience, in both small molecule and biologic products, across multiple indications and markets. Most recently, she was at Connect Biopharma, where she held the position of Vice President of Clinical Development and was responsible for creating and implementing the clinical development strategy. During her time there, she oversaw five NMPA IND approvals, three FDA IND approvals, eight clinical trial initiations and six clinical trial completions. Before then, she was Executive Director of Clinical Operations at Shanghai Haihe Pharmaceutical Company, Ltd. and Medical & Scientific Director at Servier China. Earlier, Dr. Li held multiple clinical development and medical roles at leading multinational pharmaceutical companies, including Medical Director at Takeda China, Head of the Medical Department at Bayer Healthcare, Senior Medical Manager at Xi'an Janssen and Medical Manager at Shanghai Roche. Dr. Li began her career as a cardiologist at Beijing Fuwai Heart Disease Hospital in Beijing, China.
More on Boston Chron
Dr. Li holds an MBA degree from Peking University, a Master's degree in Internal Medicine from Peking Union Medical College and a Bachelor's degree in Clinical Medicine from Beijing Medical University. She is also a licensed physician and pharmacist.
"We are delighted to welcome Dr. Li to CANbridge, where her broad experience in drug development will be instrumental to our future success as we ramp up our clinical development programs across multiple candidates and markets," said Gerry Cox, MD, Ph.D., Chief Development Strategist and Interim Chief Medical Officer, CANbridge Pharmaceuticals.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. (1228.HK) is a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 11 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School and LogicBio.
More on Boston Chron
For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.
Forward-Looking Statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
Contacts
Investor Relations:
US
Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
China
CANbridge Pharmaceuticals Inc.
ir@canbridgepharma.com
Media:
Deanne Eagle
Planet Communications
deanne@planetcommunications.nyc
917.837.5866
Dr. Li brings to CANbridge a wealth of international clinical development experience, in both small molecule and biologic products, across multiple indications and markets. Most recently, she was at Connect Biopharma, where she held the position of Vice President of Clinical Development and was responsible for creating and implementing the clinical development strategy. During her time there, she oversaw five NMPA IND approvals, three FDA IND approvals, eight clinical trial initiations and six clinical trial completions. Before then, she was Executive Director of Clinical Operations at Shanghai Haihe Pharmaceutical Company, Ltd. and Medical & Scientific Director at Servier China. Earlier, Dr. Li held multiple clinical development and medical roles at leading multinational pharmaceutical companies, including Medical Director at Takeda China, Head of the Medical Department at Bayer Healthcare, Senior Medical Manager at Xi'an Janssen and Medical Manager at Shanghai Roche. Dr. Li began her career as a cardiologist at Beijing Fuwai Heart Disease Hospital in Beijing, China.
More on Boston Chron
- The City Celebrates the Grand Opening of Barnard Place Park in South Boston
- InsideTracker Celebrates Global Running Day with Live, Virtual Event Featuring Rahaf Khatib, Sally McRae
- Starry Group Holdings, Inc. to Present at UBS Future of 5G Conference
- DOUG RENDE HAS BEEN SELECTED TO LEAD NORTH AMERICAN SPECIALTY LAMINATIONS, THE NORTH AMERICAN LEADER IN DIFFERENTIATED LAMINATED SOLUTIONS TO THE BUILDING MATERIALS INDUSTRY.
- Fantastic Sams Franchise Corporation Partners with First Development Agent in the Brand's Ambitious Expansion Initiative
Dr. Li holds an MBA degree from Peking University, a Master's degree in Internal Medicine from Peking Union Medical College and a Bachelor's degree in Clinical Medicine from Beijing Medical University. She is also a licensed physician and pharmacist.
"We are delighted to welcome Dr. Li to CANbridge, where her broad experience in drug development will be instrumental to our future success as we ramp up our clinical development programs across multiple candidates and markets," said Gerry Cox, MD, Ph.D., Chief Development Strategist and Interim Chief Medical Officer, CANbridge Pharmaceuticals.
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. (1228.HK) is a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with three approved drugs and a pipeline of 11 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. CANbridge is also building next-generation gene therapy development capability through a combination of collaboration with world-leading researchers and biotech companies and internal capacity. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the UMass Chan Medical School and LogicBio.
More on Boston Chron
- Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors
- Brian Peterson assisted Kaplan Tarps & Cargo Controls with obtaining a GSA Multiple Award Schedule
- Waters Corporation Presentation at the Jefferies 2022 Global Health Care Conference
- Boston: Mayor Wu Announces Curbside Food Waste Collection Program
- New Bill Opens the Door for Lawsuits Against the Government Based on Contaminated Drinking Water at Camp Lejeune
For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.
Forward-Looking Statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
Contacts
Investor Relations:
US
Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
China
CANbridge Pharmaceuticals Inc.
ir@canbridgepharma.com
Media:
Deanne Eagle
Planet Communications
deanne@planetcommunications.nyc
917.837.5866
Filed Under: Business
0 Comments
Latest on Boston Chron
- Up and coming POP / R&B Girl Group Releases New Music Video
- Boston: Mayor Wu Provides Updates on City Efforts to Address Unsheltered Homelessness and Substance Use Crises Centered at Massachusetts Avenue and Melnea Cass Boulevard
- Schneider Electric Ranked Energy as a Service Leader by Guidehouse Insights
- Industrial IoT edge is now creating savings and opening the door to new revenue sources for enterprises
- Black Bourbon Society Partners With Jim Beam® for the 2nd Annual Open Door Tour
- IDpack in the Cloud, the official service provider for the 2022 Memorial Cup presented by Kia
- Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients
- Eric Bohannon Joins Buoy Health Board of Directors
- ASI Launches iMIS.com Product Website, Expands Resources for Associations & Non-Profits
- Strategy Analytics: US Self-monitored Security Market to Reach $5.3B in 2027
- Suzahdi on eBay Australia in Warm Winter Leather 2022
- Paddle acquires ProfitWell to automate payments infrastructure for SaaS companies
- Stratum Nutrition® Announces Market Ready Dairy Free BLIS K12® and BLIS M18®
- CORRECTING and REPLACING Press Ganey, KidsX to Launch Pediatric Healthcare Accelerator to Address Health Issues in Lives of Children
- MC Residential LLC Names Greg Flatt Regional Vice President
- ENERGY33 is awarded an Engineering & Construction Management Contract in Honduras
- Join us Memorial Day Weekend - Sunday Brunch in Astoria, Queens
- Eastern Bank Foundation Honors CommonWealth Kitchen With A Community Advocacy Award
- Latino Leaders Network to Honor Mayor Tim Keller of Albuquerque with Antonio Villaraigosa Leadership Award at the 36th Tribute to Mayors
- Procurement Partners Welcomes Troy Thibodeau as Chief Marketing Officer